APO2L/TRAIL in Combination With Rituximab in Subjects Non-Hodgkin's Lymphoma

This study is for people with a type of slow-growing lymphoma called follicular non-Hodgkin's lymphoma (NHL) that has come back after previous treatment with rituximab. The study tests combining a new experimental drug called APO2L/TRAIL with rituximab (a standard lymphoma antibody treatment) to see if together they can better control the lymphoma. APO2L/TRAIL is designed to trigger cancer cell death. You may be eligible if: - You are 18 years of age or older - You have been diagnosed with follicular non-Hodgkin's lymphoma (CD20+, grade 1, 2, or 3a) - Your lymphoma came back or grew after a previous rituximab-containing treatment that had worked for at least 6 months - You have measurable disease on scans - You are generally well (ECOG performance status 0 or 1) - Your life expectancy is more than 3 months - You are using reliable contraception if you could become pregnant You may NOT be eligible if: - You have received chemotherapy or radiation within the last 4 weeks - You are pregnant or breastfeeding - You have HIV, hepatitis B, or hepatitis C - You have significant heart disease - You are currently taking systemic corticosteroids (like prednisone) - You have had another cancer in the last 5 years - You have had prior treatment with APO2L/TRAIL Talk to your doctor about whether this trial might be right for you.